TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: changes in clinical attachment level in deep pockets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in percent body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with high Candida counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean ocular comfort score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean reduction in corneal staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sickness absence rates
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Operation time for laparoscopic cholecystectomy (LC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Intensity of mediastinal adhesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reentry time in infants undergoing repeat median sternotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Gd-enhanced lesion volume (LV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reductions in multiple health behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of synovial membrane thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: rise of intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Total homocysteine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: excellent (≥90%) repigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: good (≥75%) repigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: colour match
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: risk perceptions
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: warning-information recall
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Time to first GI bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of death associated with GI bleeding
Endpoint domain: Mortality/survival
Primary endpoint: Viability of PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to product use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performance enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain (visual analogue score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease of nasal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease of late-phase symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of albumin influx
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: health behavior change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in VO2 peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximal strength of the triceps surae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement in walk test distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MVO (Myocardial Viability Outcomes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative pain distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse effects of analgesia
Endpoint domain: Adverse events/effects
Primary endpoint: Persistent foveal detachment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transient retinal oedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of complications (fatal and nonfatal)
Endpoint domain: Adverse events/effects
Primary endpoint: time to 0.1 mV ST depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of falling
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of recurrent CMV infection
Endpoint domain: Adverse events/effects
Primary endpoint: t(1/2abs) of (S)-ibuprofen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T(max) for (R)-ibuprofen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t(lag) for (R)-ibuprofen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity of CDS diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: specificity of CDS diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: positive predictive value of CDS diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: negative predictive value of CDS diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Word recall
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: incidence of composite primary outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Clinically evident VTE
Endpoint domain: Adverse events/effects
Primary endpoint: Critical bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: cTnI elevation >0.01 microg/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severe hypoglycemia (blood glucose < 40 mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sepsis-associated deaths
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients with >or=30% improvement in average pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients experiencing no more than mild heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chart notations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Referrals to mental health specialists
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Initial success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-year cumulative probability of graft success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking ability maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Biologically Effective Dose (BED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rest IC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Use of adjunctive antihypertensive therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Healing period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction in STH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Release of C3a
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Release of IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Release of IL-8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Recovery of the marrow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinol-binding protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antifebrile time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use frequency of ibuprofen oral liquid
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Granularity Index (GI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Remission rate with cyclophosphamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission rate with rituximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean concentrations of alanine transaminase (ALT), aspartate transaminase (AST) and total bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum α‐tocopherol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 4 (serious) adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: daytime defecation frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: resting anal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: maximum squeeze pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 3-year event-free survival (3-y-EFS)
Endpoint domain: Mortality/survival
Primary endpoint: 3-year overall survival (3-y-OS)
Endpoint domain: Mortality/survival
Primary endpoint: retching episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sustained virological response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality rates at 15 days
Endpoint domain: Mortality/survival
Primary endpoint: TTP relapse rates after one-year ticlopidine therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kidney length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: incidence of severe bladder injury
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of other complications
Endpoint domain: Adverse events/effects
Primary endpoint: postoperative stay duration
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Measures of respiratory illnesses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Use of health care services
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: freedom from atrial tachyarrhythmias (AF/AT) off antiarrhythmic drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 12 mo mortality among infants
Endpoint domain: Mortality/survival
Primary endpoint: frequency of angina events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: acute exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: step-up treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of spinal anaesthesia performed at or above L2-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular events/cardiovascular mortality
Endpoint domain: Mortality/survival
Primary endpoint: yearly incidence of severe hypoglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of NV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Administered RAI dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fiberoptic glottis view grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skeletal-related events (SREs)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in serum TC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in HDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to wake up (minutes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total time under sedative control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dosages of midazolam and propofol (mg×kg(‐1) ×h(‐1))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CFA (Clinical Function Assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CNA (Clinical Nutritional Assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of malabsorption signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: spontaneous transpyloric migration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Interval from induction to delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 AUC0‐12 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in stunting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean total summed knowledge score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: rate of skin flora contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: KOOS pain subscores (pain reduction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum programmed cell death protein 1 (PD‐1) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: resting state functional connectivity (rsFC) of the DLPFC-SMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidence of definite awareness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of blood staining
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical improvement criteria attainment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lequesne's index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: eGFR as a predictor of adiponectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Plasma leptin association with HOMA-IR index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tibial rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total MMP-2 serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Active MMP-2 fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: apolipoprotein A-I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nondipping SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nondipping MAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nondipping DBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of passes needed for optimal guidewire placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of adolescents who used a condom at last sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attention to fearful facial expressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratings of positivity of images with social content
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acute clinical endpoints achieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum concentrations of total IGF‐1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum concentrations of IGFBP‐3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Increased physical activity scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Vigorous activity increase
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Length of the encounter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completeness of genograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lifetime IPV victimization prevalence
Endpoint domain: Adverse events/effects
Primary endpoint: Past year IPV victimization prevalence
Endpoint domain: Adverse events/effects
Primary endpoint: Lifetime IPV perpetration prevalence
Endpoint domain: Adverse events/effects
Primary endpoint: Past year IPV perpetration prevalence
Endpoint domain: Adverse events/effects
Primary endpoint: Parental empowerment score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maxillary inter-molar width increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deciduous inter-second molar width increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skeletal maxillary transverse dimension increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of correct responses on the GOT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: body image distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction of mutans streptococci in interproximal plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in Quigley & Hein plaque index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in gastric pHi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Increase in oxygen delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rectal pressure during evacuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pain Interference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of Ventricular Arrhythmias (VA)
Endpoint domain: Mortality/survival
Primary endpoint: Risk of Ventricular Arrhythmias or Death (VA/death)
Endpoint domain: Mortality/survival
Primary endpoint: pain scores at rest and cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG spectral power during sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bowel function score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Constipation prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Soiling prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: primary composite outcome index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean side-to-side difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median sputum wet weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to recovery of motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Major Depressive Disorder (MDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of vulvar and vaginal LSILs and HSILs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Moderate or severe neurological disability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Three-year local recurrence rates
Endpoint domain: Mortality/survival
Primary endpoint: Tinnitus-specific distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bruising occurrence percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pain period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: length of stricture in case of recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: supplemental opioid requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Viral outcomes
Primary endpoint: Proportion of patients with undetectable HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Viral outcomes
Primary endpoint: Decreased pulmonary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Grade ≥3 treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in overall symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Trait anxiety change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trait depression change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of Von Willebrand factor and other thrombotic markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes